Royal Bank of Canada’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-61,571
| Closed | -$2.12M | – | 7519 |
|
|
2020
Q3 | $2.12M | Sell |
61,571
-94,353
| -61% | -$2.01M | ﹤0.01% | 2647 |
|
|
2020
Q2 | $2.6M | Sell |
155,924
-1,378
| -0.9% | -$23.4K | ﹤0.01% | 2419 |
|
|
2020
Q1 | $2.27M | Sell |
157,302
-7,031
| -4% | -$180K | ﹤0.01% | 2380 |
|
|
2019
Q4 | $5.5M | Sell |
164,333
-5,223
| -3% | -$146K | ﹤0.01% | 2089 |
|
|
2019
Q3 | $3.55M | Buy |
169,556
+39,778
| +31% | +$812K | ﹤0.01% | 2316 |
|
|
2019
Q2 | $2.7M | Buy |
129,778
+12,099
| +10% | +$249K | ﹤0.01% | 2526 |
|
|
2019
Q1 | $2.63M | Buy |
117,679
+29,963
| +34% | +$705K | ﹤0.01% | 2483 |
|
|
2018
Q4 | $2.1M | Buy |
87,716
+9,939
| +13% | +$257K | ﹤0.01% | 2608 |
|
|
2018
Q3 | $2.12M | Buy |
77,777
+59,901
| +335% | +$1.69M | ﹤0.01% | 2805 |
|
|
2018
Q2 | $480K | Buy |
17,876
+413
| +2% | +$12.6K | ﹤0.01% | 3814 |
|
|
2018
Q1 | $555K | Buy |
17,463
+17,076
| +4,412% | +$601K | ﹤0.01% | 3630 |
|
|
2017
Q4 | $15K | Sell |
387
-2,882
| -88% | -$93K | ﹤0.01% | 5715 |
|
|
2017
Q3 | $81K | Buy |
3,269
+3,190
| +4,038% | +$68.8K | ﹤0.01% | 5152 |
|
|
2017
Q2 | $1K | Sell |
79
-747
| -90% | -$14.3K | ﹤0.01% | 6478 |
|
|
2017
Q1 | $19K | Sell |
826
-1,373
| -62% | -$28.2K | ﹤0.01% | 5664 |
|
|
2016
Q4 | $45K | Buy |
2,199
+2,117
| +2,582% | +$43.3K | ﹤0.01% | 5324 |
|
|
2016
Q3 | $1K | Buy |
+82
| New | +$1.11K | ﹤0.01% | 6336 |
|
|
2016
Q1 | – | Sell |
-20
| Closed | – | – | 6800 |
|
|
2015
Q4 | $0 | Sell |
20
-380
| -95% | -$7.03K | ﹤0.01% | 6941 |
|
|
2015
Q3 | $10K | Buy |
+400
| New | +$9.35K | ﹤0.01% | 5899 |
|
Royal Bank of Canada's AIMT Position: Q4 2020 in Review
Royal Bank of Canada sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 61,571 shares — an estimated $2.12M sold.
Royal Bank of Canada first reported a position in AIMT in Q3 2015 and held it in 19 quarters. The position peaked at $5.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Royal Bank of Canada reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Royal Bank of Canada sold 61,571 Aimmune Therapeutics shares in Q4 2020, an estimated $2.12M.
- Royal Bank of Canada first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 19 quarters.
- Royal Bank of Canada's Aimmune Therapeutics position peaked at $5.5M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Royal Bank of Canada's 13F filing for Q4 2020, filed 16 Feb 2021.